Application Serial No.: 10/619,253

DOCKET NO.: 4042.3007 US (ISPH-0590US.P1)

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listing of claims in the instant application:

- 1. (Currently amended) An antisense compound 15 to 25 nucleobases in length targeted to a nucleic acid molecule encoding human stearoyl-CoA desaturase, wherein the antisense compound specifically hybridizes with at least 90% complementarity to a sequence within the range of nucleotides 2989 to 3054 of SEQ ID NO: 3 with at least 90% complementarity and inhibits the expression of human stearoyl-CoA desaturase.
- 2. (Previously presented) The antisense compound according to claim 1, which is an antisense oligonucleotide.
 - 3. (Canceled)
- 4. (Previously presented) The antisense compound according to claim 2, wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.
- 5. (Previously presented) The antisense compound according to claim 4, wherein the modified internucleoside linkage is a phosphorothioate linkage.
- 6. (Previously presented) The antisense compound according to claim 2, wherein the antisense oligonucleotide comprises at least one modified sugar moiety.
- 7. (Previously presented) The antisense compound according to claim 6, wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.
- 8. (Previously presented) The antisense compound according to claim 2, wherein the antisense oligonucleotide comprises at least one modified nucleobase.
- 9. (Previously presented) The antisense compound according to claim 8, wherein the modified nucleobase is a 5-methylcytosine.
- 10. (Previously presented) The antisense compound according to claim 2, wherein the antisense oligonucleotide is a chimeric oligonucleotide.

Application Serial No.: 10/619,253

DOCKET NO.: 4042.3007 US (ISPH-0590US.P1)

- 11.-20. (Canceled)
- 21. (Previously presented) A composition comprising the antisense compound of claim 1 and a pharmaceutically acceptable carrier or diluent.
 - 22.-35. (Canceled)
- 36. (Currently amended) The antisense compound according to claim 1, wherein said <u>antisense</u> compound comprises the nucleotide sequence of SEQ ID NO: 29, 30, 124, or 125.
 - 37. (Canceled)
- 38. (Currently amended) The antisense compound according to claim 1, wherein said <u>antisense</u> compound consists of the nucleotide sequence of SEQ ID NO: 29, 30, 124, or 125.